Summary
CELG is a lot cheaper than this time last year.
I look at the threat to Revlimid from generics manufacturers.
I comment on the ongoing ozanimod story.
Celgene Corporation (CELG) has had a less than ideal past 10 months. Hitting highs in early October 2017 of $147.17, the stock fell to $74.13 in May 2018. A 50 percent drop, or a 50 percent pop, is standard for many of the smaller biotechs I cover, but not normally, the domain of a $60B biopharmaceutical giant like CELG. A lot of the factors that led to the drop of CELG are in the past now, and the focus of this article isn't to dwell on those. Unfortunately, other factors which have weighed on the stock are still in play. This article will look at a few of those factors and try to decide if the bottom is in on CELG or if it is even clever to try and call the bottom.
Figure 1: Past 12 months of CELG price action with annotation of negatives. There have been some positives and looking at the past few months it might appear the bottom is in. MS, Morgan Stanley. Source: Chart from StockCharts.com, annotations by Biotech Beast.
